Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.
about
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Combination of AKT inhibitor A ...... l of hepatocellular carcinoma.
@en
Combination of AKT inhibitor A ...... l of hepatocellular carcinoma.
@nl
type
label
Combination of AKT inhibitor A ...... l of hepatocellular carcinoma.
@en
Combination of AKT inhibitor A ...... l of hepatocellular carcinoma.
@nl
prefLabel
Combination of AKT inhibitor A ...... l of hepatocellular carcinoma.
@en
Combination of AKT inhibitor A ...... l of hepatocellular carcinoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Combination of AKT inhibitor A ...... el of hepatocellular carcinoma
@en
P2093
Ayca Zeybek Kuyucu
Giovanni Abbadessa
Keerthi Kurma
Nathalie Sturm
Séyédéh Tayébéh Ahmad Pour
Zuzana Macek Jilkova
P2860
P304
11145-11158
P356
10.18632/ONCOTARGET.24298
P407
P577
2018-01-23T00:00:00Z